Enzyme replacement in fabry disease: The essence is in the kidney

Annals of Internal Medicine

Volumn 146, Issue 2, 2007, Pages 142-144

  Schiffmann, Raphael ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; ALPHA GALACTOSIDASE; ISOENZYME;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; EDITORIAL; ENZYME REPLACEMENT; FABRY DISEASE; GLOMERULUS FILTRATION RATE; HEART DISEASE; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; FEMALE; MALE; NOTE; PATHOPHYSIOLOGY;

ALPHA-GALACTOSIDASE; FABRY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; ISOENZYMES; MALE;

EID: 33846909516     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-146-2-200701160-00147     Document Type: Editorial

References (20)